$ABEO (Abeona Therapeutics) – Weekly Chart AnalysisThe Daily structure is showing an early-stage bullish reversal after a prolonged multi-year downtrend. Price has established a higher low above the long-term demand zone and is now attempting to build a sustainable accumulation base. As long as buyers defend the current support area, the probability
Abeona Therapeutics Inc.
No trades
No trades
Compare with Abeona Therapeutics Inc.
Key facts today
Abeona Therapeutics (ABEO) is set to report Q2 2026 results: analysts forecast revenue $12.24M (up from $0.4M year‑ago) and EPS loss $0.23 per share. 1
1.30 USD
71.18 M USD
5.82 M USD
50.39 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Details
Sector
Industry
CEO
Vishwas Seshadri
Website
Headquarters
Cleveland
Founded
1974
IPO date
Sep 19, 1980
ISIN
US00289Y2063
CUSIP
00289Y206
FIGI
BBG000DT5D52
Identifiers
ISIN US00289Y2063
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
ABEO Solid financial + Technical setupABEO is transitioning from a speculative R&D firm to a commercial-stage powerhouse.
While trailing P/E and ROA are distorted by one-time gains, the forward growth curve justifies the current technical breakout.
Buy the confirmation above $6.00, but keep a tight leash on the trade into the May 13
Looking for 10x surge stock, Here it is
Abeona Therapeutics Inc. (NASDAQ: ABEO) is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious and life-threatening diseases, with a focus on rare genetic disorders.
This company stock has been under performing for past 5 years with decline rate of 99% from
Abeo🔍 Technical Analysis – Daily Chart
🟩 Entry Zone: $5.32 – $5.20
Support Zone: Price is currently sitting within a well-defined support zone (green area), which has acted as a significant demand area in the past (late May and mid-April).
This zone shows multiple price reactions, making it a key accu
ABEOABEO is currently trading at $5.58 and is expected to pull back toward the green zone to retest the previously broken descending trendline and the strong demand area between $4.75 and $5.08.
This zone is considered a key support level, where buying pressure has been historically strong. A successful
ABEO is undervalued; Market has NOT priced in FDA approval news.Looks like a good monthly or longer play for the following reasons:
1. Beginning to see elevated RVOL (although it is Pre) in the hundreds.
2. recent fantastic news, the MAIN drug they are developing received FDA approval, this cannot be understated as a) it makes all previous revenues from quarte
ABEOABEO stock presents one of the best opportunities in the US market, with target prices well above $100. It is an excellent stock for investors. Currently, the stock is in a weekly upward trend and has broken through a strong supply zone from which it had bounced multiple times before. Now, it is pul
ABEO Long PositionABEO has a nice Long setup .
Ma cross 32/72 strategy on weekly timeframe
with 1.5 reward to risk ratio .
Entry around 4.78 cents
Stop is at 3.63 cents , which is the low of the bottom of the candle of the MA cross
target is 6.50 cents
, indicators on chart is insane oscillator from T
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
The current price of ABEO is 7.40 USD — it has decreased by −0.67% in the past 24 hours. Watch Abeona Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Abeona Therapeutics Inc. stocks are traded under the ticker ABEO.
ABEO stock has risen by 13.85% compared to the previous week, the month change is a 3.93% rise, over the last year Abeona Therapeutics Inc. has showed a 18.21% increase.
We've gathered analysts' opinions on Abeona Therapeutics Inc. future price: according to them, ABEO price has a max estimate of 28.00 USD and a min estimate of 14.00 USD. Watch ABEO chart and read a more detailed Abeona Therapeutics Inc. stock forecast: see what analysts think of Abeona Therapeutics Inc. and suggest that you do with its stocks.
ABEO reached its all-time high on May 22, 1981 with the price of 5,437,500.00 USD, and its all-time low was 2.19 USD and was reached on Feb 24, 2023. View more price dynamics on ABEO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ABEO stock is 3.52% volatile and has beta coefficient of 2.20. Track Abeona Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Abeona Therapeutics Inc. there?
Today Abeona Therapeutics Inc. has the market capitalization of 421.76 M, it has decreased by −6.23% over the last week.
Yes, you can track Abeona Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Abeona Therapeutics Inc. is going to release the next earnings report on Aug 13, 2026. Keep track of upcoming events with our Earnings Calendar.
ABEO earnings for the last quarter are −0.30 USD per share, whereas the estimation was −0.34 USD resulting in a 10.45% surprise. The estimated earnings for the next quarter are −0.23 USD per share. See more details about Abeona Therapeutics Inc. earnings.
Abeona Therapeutics Inc. revenue for the last quarter amounts to 8.72 M USD, despite the estimated figure of 4.57 M USD. In the next quarter, revenue is expected to reach 12.24 M USD.
ABEO net income for the last quarter is −17.07 M USD, while the quarter before that showed −20.46 M USD of net income which accounts for 0.00% change. Track more Abeona Therapeutics Inc. financial stats to get the full picture.
No, ABEO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 12, 2026, the company has 226 employees. See our rating of the largest employees — is Abeona Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Abeona Therapeutics Inc. EBITDA is −89.14 M USD, and current EBITDA margin is −1.48 K%. See more stats in Abeona Therapeutics Inc. financial statements.
Like other stocks, ABEO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Abeona Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Abeona Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Abeona Therapeutics Inc. stock shows the buy signal. See more of Abeona Therapeutics Inc. technicals for a more comprehensive analysis.









